Yi Ba
Impact in
- Cancer Research top 0.1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 0.5%
- Circular RNAs in diseases
- Extracellular vesicles in disease
- RNA modifications and cancer
- RNA Interference and Gene Delivery
Papers in
-
- MicroRNA in disease regulation 41
- Cancer-related molecular mechanisms research 27
- Oncology 63
- Colorectal Cancer Treatments and Studies 22
- Co-authors
- Ting Deng (58 shared papers)Haiyang Zhang (40 shared papers)Guoguang Ying (24 shared papers)Haiou Yang (9 shared papers)Jialu Li (12 shared papers)Tao Ning (26 shared papers)Shaohua Ge (26 shared papers)Tao Ning (12 shared papers)
- Journals
- 癌症：英文版 (7 papers)BMC Cancer (6 papers)Annals of Oncology (6 papers)Medical Oncology (4 papers)Oncotarget (4 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Yi Ba
196 papers receiving 17.1k citations
Yi Ba's Hit Papers
Peers
Comparison fields: 5 of 157
- Cancer Research 8.4k
- Molecular Biology 9.1k
- Oncology 2.7k
- Pulmonary and Respiratory Medicine 2.2k
- Immunology 1.0k
Countries citing papers authored by Yi Ba
This map shows the geographic impact of Yi Ba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi Ba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi Ba more than expected).
Fields of papers citing papers by Yi Ba
This network shows the impact of papers produced by Yi Ba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi Ba. The network helps show where Yi Ba may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi Ba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 206 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases Hit paper breakdown → | 2008 | 4007 |
| 2 | Secreted Monocytic miR-150 Enhances Targeted Endothelial Cell Migration Hit paper breakdown → | 2010 | 1047 |
| 3 | Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA Hit paper breakdown → | 2011 | 985 |
| 4 | CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer Hit paper breakdown → | 2020 | 843 |
| 5 | Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction Hit paper breakdown → | 2016 | 810 |
| 6 | Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma Hit paper breakdown → | 2021 | 558 |
| 7 | 2009 | 493 | |
| 8 | Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study Hit paper breakdown → | 2020 | 486 |
| 9 | 2017 | 475 | |
| 10 | Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancer Hit paper breakdown → | 2020 | 434 |
| 11 | Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 Hit paper breakdown → | 2019 | 371 |
| 12 | 2010 | 369 | |
| 13 | 2011 | 343 | |
| 14 | 2013 | 286 | |
| 15 | 2011 | 248 | |
| 16 | 2018 | 187 | |
| 17 | Adipocyte‐Derived Exosomal MTTP Suppresses Ferroptosis and Promotes Chemoresistance in Colorectal Cancer Hit paper breakdown → | 2022 | 184 |
| 18 | 2020 | 167 | |
| 19 | 2021 | 160 | |
| 20 | 2014 | 149 |
About Yi Ba
Yi Ba is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Surgery, having authored 206 papers that have together received 17.3k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (41 papers), Cancer-related molecular mechanisms research (27 papers), Colorectal Cancer Treatments and Studies (22 papers), Circular RNAs in diseases (21 papers), Gastric Cancer Management and Outcomes (19 papers), Extracellular vesicles in disease (10 papers), Esophageal Cancer Research and Treatment (10 papers) and RNA modifications and cancer (8 papers). The work is most often cited by research in Cancer Research (8.4k citations), Molecular Biology (9.1k citations), Oncology (2.7k citations), Pulmonary and Respiratory Medicine (2.2k citations) and Immunology (1.0k citations). Yi Ba has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Ting Deng, Haiyang Zhang, Guoguang Ying, Haiou Yang, Jialu Li, Tao Ning, Shaohua Ge, Tao Ning, Rui Liu and Dingzhi Huang. Their work appears in journals such as 癌症：英文版, BMC Cancer, Annals of Oncology, Medical Oncology and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.